Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis (Q37783433)

23 August 2017

title

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis (English)

1 reference

23 August 2017

0 references

multiple drug resistance

1 reference

3

1 reference

Giovanni Battista Migliori

23 August 2017

Giovanni Sotgiu

2

0 references

object named as

Giovanni Battista Migliori

series ordinal

4

0 references

author name string

José A Caminero

series ordinal

1

1 reference

23 August 2017

publication date

1 September 2010

1 reference

Lancet Infectious Diseases

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

621-629

1 reference

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Comprehensive treatment of extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Multidrug- and extensively drug-resistant tuberculosis, Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Extensively drug-resistant tuberculosis: is its definition correct?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

The treatment of multidrug-resistant tuberculosis in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Management of multidrug-resistant tuberculosis and patients in retreatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Drug-susceptibility testing in tuberculosis: methods and reliability of results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Clinical and operational value of the extensively drug-resistant tuberculosis definition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

The clinical relevance of Mycobacterial pharmacogenetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Late results in re-treatment of patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Late results of treatment of chronic drug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Fluoroquinolones, tuberculosis, and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Outpatient gatifloxacin therapy and dysglycemia in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Studies on the cross-resistance of Mycobacterium tuberculosis, strain H37Rv, to aminoglycoside- and peptide-antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Pharmacokinetic evaluation of para-aminosalicylic acid granules.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Antituberculosis activities of clofazimine and its new analogs B4154 and B4157

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Imipenem for treatment of tuberculosis in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970139-0

7 January 2021

10.1016/S1473-3099(10)70139-0

Identifiers

DOI

1 reference

23 August 2017

1 reference